A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
Pfizer
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Regeneron Pharmaceuticals
AVEO Pharmaceuticals, Inc.
SecuraBio
Novartis
Bristol-Myers Squibb
Telix Pharmaceuticals (Innovations) Pty Limited
Celgene
Novartis
Verity Pharmaceuticals Inc.
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
AstraZeneca
Pfizer
Genmab
Pfizer
Qilu Pharmaceutical Co., Ltd.
CSPC Megalith Biopharmaceutical Co.,Ltd.
Regeneron Pharmaceuticals
Hoffmann-La Roche
Shanghai Miracogen Inc.
Newave Pharmaceutical Inc
Novartis
Alexion Pharmaceuticals, Inc.
Chengdu Zenitar Biomedical Technology Co., Ltd
Tesaro, Inc.
Celgene
AbbVie
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Regeneron Pharmaceuticals
BeiGene
Antengene Corporation
BeiGene
Genmab
Bristol-Myers Squibb
Chipscreen Biosciences, Ltd.
Karyopharm Therapeutics Inc
Amgen
Celgene
Amgen
CStone Pharmaceuticals
Mersana Therapeutics
pharmaand GmbH
AbbVie
Guangzhou Gloria Biosciences Co., Ltd.
Amgen
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Celgene